Publications by Xiaomeng Hu | EPFL Graph Search

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Messenger RNA (mRNA) vaccines have made remarkable public health contributions during the pandemic and initiated a new era for nucleic acid–based therapeutics. With the unique strength of nucleic acids, including not only mRNA but also DNA, microRNA, small ...

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

A versatile and highly effective platform remains a major challenge in the development of personalized cancer vaccines. Here, we devised a redox-responsive polycondensate neoepitope (PNE) through a reversible polycondensation reaction of peptide neoantigen ...

Xiaomeng Hu

Chat with Graph Search

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Delivery approaches of immunomodulatory nucleic acids for cancer therapy

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine